# Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma

> **NCT03465592** · PHASE1,PHASE2 · RECRUITING · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 39 (estimated)

## Conditions studied

- Sarcoma
- Solid Tumor, Adult
- Solid Tumor, Childhood

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03465592
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-05-01
- **Primary completion:** 2027-01
- **Final completion:** 2029-03
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2026-02-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03465592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03465592, "Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT03465592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*